Tsubokura Yukie, Satake Atsushi, Hotta Masaaki, Yoshimura Hideaki, Fujita Shinya, Azuma Yoshiko, Nakanishi Takahisa, Nakaya Aya, Ito Tomoki, Ishii Kazuyoshi, Nomura Shosaku
First Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata City, Osaka, 573-1010, Japan.
Int J Hematol. 2016 Dec;104(6):744-748. doi: 10.1007/s12185-016-2087-y. Epub 2016 Aug 29.
A humanized anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, mogamulizumab (MOG), has been shown to be safe and effective in the treatment of relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). MOG depletes ATLL cells as well as regulatory T cells (Tregs), as CCR4 is expressed on these cells as well. In this context, pretransplant treatment with MOG may induce severe graft-versus-host disease (GVHD) in allogeneic hematopoietic stem-cell transplantation (HSCT). However, the influence of MOG on allogeneic HSCT, including its induction of GVHD, is unclear. In this report, we describe two patients treated with MOG who subsequently underwent allogeneic HSCT. They did not develop severe GVHD or treatment-related complications. In addition, we examined the kinetics of Tregs in the second case. Finally, we suggest that the detrimental effects of MOG can be avoided, which should be prospectively evaluated in future studies.
人源化抗CC趋化因子受体4（CCR4）单克隆抗体莫加莫单抗（MOG）已被证明在治疗复发/难治性成人T细胞白血病/淋巴瘤（ATLL）方面安全有效。MOG可消耗ATLL细胞以及调节性T细胞（Tregs），因为这些细胞上也表达CCR4。在这种情况下，移植前用MOG治疗可能会在异基因造血干细胞移植（HSCT）中诱发严重的移植物抗宿主病（GVHD）。然而，MOG对异基因HSCT的影响，包括其对GVHD的诱导作用尚不清楚。在本报告中，我们描述了两名接受MOG治疗后随后进行异基因HSCT的患者。他们没有发生严重的GVHD或治疗相关并发症。此外，我们在第二个病例中检查了Tregs的动力学。最后，我们认为可以避免MOG的有害影响，这一点应在未来的研究中进行前瞻性评估。
Zotero 插件